CASC3 and plasma cell myeloma: Bioinformatics analysis showed 2996 sites with altered methylation (only hypomethylated) in myeloma cells treated three times with BTZ and a methylation inhibitor compared to cells treated three times with BTZ alone (Figure 2B).